The family history of cancer – a common concern in palliative care

2004 ◽  
Vol 12 (2) ◽  
pp. 59-66 ◽  
Author(s):  
Judy Kirk
BMJ ◽  
1884 ◽  
Vol 1 (1222) ◽  
pp. 1039-1040 ◽  
Author(s):  
W. R. Williams

2016 ◽  
Vol 52 (6) ◽  
pp. e153
Author(s):  
Jude Emmanuel Cléophat ◽  
Catherine Gonthier ◽  
Pierre Gagnon ◽  
Ana Marin ◽  
Jocelyne Chiquette ◽  
...  

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e12588-e12588
Author(s):  
Yen Yen Tan ◽  
Daniela Muhr ◽  
Christine Rappaport-Fuerhauser ◽  
Daphne Gschwantler-Kaulich ◽  
Christoph Grimm ◽  
...  

e12588 Background: We assessed the prevalence of family history and its association with germline BRCA1/2mutation status/location and age at onset in triple-negative breast cancer (TNBC) patients. Methods: 266 patients with TNBC < 60 years unselected for family history of cancer were enrolled and germline DNA was sequenced to identify mutations. Family pedigrees were prospectively collected from these patients. Logistic regression was used to investigate family history and its association with mutation type/location and age at onset. ROC curves were constructed to determine good predictors of BRCAmutations. Results: BRCA mutations were identified in 18.0% of all patients (15.0% BRCA1, 3.0% BRCA2). BRCA1 carriers have a significantly earlier age at onset than non-mutation carriers (40 vs 49 years; p < .001). While 39/124 (31.4%) patients with family history of cancer carried a BRCA1/2 mutation, 9/142 (6.3%) BRCA carriers had no family history of cancer. BRCA1 carriers with ≥1BC in the family are commonly identified in the breast cancer cluster regions (53.1%). BRCA2 carriers more commonly cluster within the ovarian cancer regions. Of note, this difference was not statistically significant. Women with mutations in BRCA1 OCCR are diagnosed at a younger age. TNBC diagnosed ≤45 years with ≥1BC and ≥1OC in the family are good predictors of BRCA1 mutation (AUC 0.867). Conclusions: Young women with TNBC and a family history of BC and OC are likely to have a BRCA mutation. Specific BRCA mutation locations may add to the identification of a subgroup of TNBC patients with a relatively higher risk of subsequent ovarian cancer. Identification of high-risk TNBC patients with BRCA1 mutation will enable clinicians to optimize cancer management for this phenotype, but will require further validation in larger studies.


2017 ◽  
Vol 17 (2) ◽  
pp. 303-307 ◽  
Author(s):  
Catherine Gonthier ◽  
Sylvie Pelletier ◽  
Pierre Gagnon ◽  
Ana Marin ◽  
Jocelyne Chiquette ◽  
...  

2015 ◽  
Vol 37 (4) ◽  
pp. 272-276 ◽  
Author(s):  
L G Buchynska ◽  
O Brieieva ◽  
K N Nekrasov ◽  
S V Nespryadko

Aim: To assess the expression of mismatch repair (MMR) proteins MSH2 and MLH1 and carry out microsatellite analysis in patients with endometrial cancer (EC) with regard to the family history of cancer. Materials and Methods: Morphological and immunohistochemical study was performed on tumor tissue samples of 49 EC patients. Microsatellite instability was determined using PCR with primers which flank microsatellite region BAT-26. Results: A tendency to a decreased expression of both MSH2 and MLH1 markers in a group of EC patients with a family history of cancer as compared with a group without aggregation of cancer in family history was observed (labeling index — LI — was 36.1 ± 8.1% and LI 20.7 ± 9.1% versus LI 48.0 ± 5.8% and 33.8 ± 5.8%, respectively). It was determined that the number of EC patients with tumors deficient by expression of MMR markers was reliably higher in a group of patients with a family history of cancer than in a group of patients without aggregation of cancer in fami ly history (р < 0.05). It was shown that in a group of EC patients with a family history of cancer, MMR-proficient tumors were detected in 38.5% of cases. Microsatellite instability was determined in 10.7% of EC patients including one patient with aggregation of Lynch-associated tumors in family history. Conclusion: Family history of cancer of EC patients is associated with malfunctioning of the MMR system as well as may be related to alternative molecular mechanisms.


2013 ◽  
Vol 16 (11) ◽  
pp. 1350-1355 ◽  
Author(s):  
Neeta S. Lakhani ◽  
Jamie Weir ◽  
Anna Allford ◽  
Joe Kai ◽  
Julian G. Barwell

Sign in / Sign up

Export Citation Format

Share Document